Large-Capacity Antibody Library: Built upon a fully human antibody library containing over 240 billion antibodies, it offers extensive diversity and flexibility to facilitate the screening of optimal candidates.

Enhanced Druggability: The inclusion of a fully synthetic antibody library improves antibody druggability, ensuring excellent stability, manufacturability, and binding specificity.

Single-Domain Antibody Library Applications: Equipped with a fully human single-domain antibody library, it significantly advances the development of next-generation therapies such as bispecific CAR-T cells and bi- and multi-specific antibodies.

R&D Achievements and Translation Efficiency: Approximately 20 internal R&D programs have been initiated to date, with four candidates advancing to clinical stages. This validates an efficient discovery-to-CAR-T engine that shortens development cycles, reduces program risks, and expands the exploratory pipeline.

Integrated Cutting-Edge Technologies: Combines state-of-the-art single-cell analysis and next-generation sequencing to accelerate CAR-T discovery and optimization.

Comprehensive Functional Profiling: Enables high-throughput screening to allow for rapid evaluation of a large pool of CAR-T lead candidates based on key phenotypic characteristics and functional metrics.

Significantly Accelerated Timelines: Advanced analytical capabilities drastically reduce screening time, streamlining the path to preclinical and clinical stages.

Enhanced Targeting: Genetic engineering of viral vector surface proteins improves selective T cell transduction in vivo, minimizing off-target risks.

Cell-Specific Expression: The use of T cell-specific promoters restricts CAR expression to the intended cell type, improving safety.

Immune Evasion: Proprietary envelope modifications prevent the elimination of the viral vector by macrophages and T cells.

Scalable Production: Suspension-adapted packaging cell lines and advanced chromatographic purification boost the yield and quality of viral vectors for clinical applications.

Expert Leadership: Led by an experienced management team with deep expertise in biologics R&D, manufacturing, and quality control.

End-to-End System: Supports a highly efficient and tightly controlled, full-spectrum manufacturing and quality system designed to ensure consistency, scalability, and compliance with global regulatory standards.

Seamless Transition: Designed to seamlessly support the transition from early-stage development to commercial-scale production, including the development of a "China solution" for global expansion.

Comprehensive Modules: Encompasses plasmid development and production, lentiviral vector development and production (for both ex vivo and in vivo applications), and the distinctive FAST CAR-T platform, each offering specific advantages in CAR-T development.

Strategic Joint Laboratory: We have established a joint laboratory with a leading top-tier Chinese hospital, fostering deep integration of research and clinical practice.

Novel Target Discovery: We are focused on exploring potential new targets and investigating novel mechanisms of action to pave the way for first-in-class drugs.

Efficient Clinical Translation: Our strong clinical network and translational expertise enable us to efficiently bridge the gap between preclinical research and clinical application, accelerating candidates into clinical stages.

Integrated Development Model: This integrated approach significantly shortens development timelines and facilitates the generation of critical clinical data to guide further development.